Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection of vaccinated individuals is increasingly common with the circulation of highly immune evasive and transmissible Omicron variants. Here, we report the dynamics and durability of recalled spike-specific humoral immunity following Omicron BA.1 or BA.2 breakthrough infection, with longitudinal sampling up to 8 months after infection. Both BA.1 and BA.2 infections robustly boosted neutralization activity against the infecting strain while expanding breadth against BA.4, although neutralization activity was substantially reduced for the more recent XBB and BQ.1.1 strains. Cross-reactive memory B cells against both ancestral and Omicron spike were predominantly expanded by infection, with limited recruitment of de novo Omicron-specific B cells or antibodies. Modeling of neutralization titers predicts that protection from symptomatic reinfection against antigenically similar strains will be durable but is undermined by new emerging strains with further neutralization escape.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361595 | PMC |
| http://dx.doi.org/10.1126/sciadv.adg5301 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potassium-competitive acid blockers.
Curr Opin Gastroenterol
July 2025
Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.
Purpose Of Review: Acid suppression is the mainstay of management of common foregut disorders, including gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori infection. Drawbacks of standard management with proton pump inhibitors (PPIs) include acid lability requiring enteric coating, slow onset of effect, lack of suppression of nocturnal acid breakthrough, and need for administration before meals.
Recent Findings: Potassium-competitive acid blockers (PCABs) are a novel class of acid suppressants that are effective in the management of symptomatic and erosive GERD, peptic ulcer disease and H.
Breakthrough SARS-CoV-2 outcomes in immune-disordered people during the Omicron era: a prospective cohort study.
BMJ Public Health
August 2025
Epidemiology and Data Management Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases Division of Intramural Research, Bethesda, Maryland, USA.
Introduction: Immune-deficient/disordered people (IDP) elicit a less robust immune response to COVID-19 vaccination than the general US population. Despite millions of IDP at presumed elevated risk, few population-level studies of IDP have been conducted in the Omicron era to evaluate breakthrough infection-related outcomes.
Methods: We followed a prospective cohort of 219 IDP and 63 healthy volunteers (HV) in the USA from April 2021 (Alpha variant peak) to July 2023 (Omicron XBB variant peak).
Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma.
Oncol Res
September 2025
Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Cholangiocarcinoma (CCA) is a fatal bile duct malignancy. CCA is intrinsically resistant to standard chemotherapy, responds poorly to it, and has a poor prognosis. Effective treatments for cholangiocarcinoma remain elusive, and a breakthrough in CCA treatment is still awaited.
View Article and Find Full Text PDFSafety, immunogenicity and efficacy of the Shingrix vaccine in immunocompromised varicella zoster virus naïve pediatric patients.
Vaccine
September 2025
Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital/ University Medical Center Utrecht, Utrecht, the Netherlands; Faculty of Medicine, Utrecht University, Utrecht, the Netherlands.
Background: Pediatric patients with autoimmune and inflammatory diseases often require immunosuppressive therapy, which increases their susceptibility to infections, including varicella-zoster virus (VZV). While the live attenuated varicella vaccine is contraindicated in most immunocompromised children, the recombinant subunit vaccine, Shingrix, may offer an alternative preventive strategy. However, data on its safety, immunogenicity, and efficacy in pediatric VZV-naïve patients remain limited.
View Article and Find Full Text PDFAffinity Maturation and Light-Chain-Mediated Paratope Diversification Anticipate Viral Evolution.
bioRxiv
August 2025
Department of Medicine, Division of Allergy and Clinical Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA, Broad Institute of MIT, and Harvard, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
A key goal of vaccinology is to train the immune system to combat current pathogens while simultaneously preparing it for future evolved variants. Understanding factors contributing to anticipatory breadth, wherein affinity maturation against an ancestral strain yields neutralization capacity against evolved variants, is therefore of great importance. Here, we investigated the mechanism of anticipatory breadth development in a public antibody family targeting the functionally restricted ACE2 binding site on SARS-CoV-2.
View Article and Find Full Text PDF